Prelude Capital Management, LLC Invitae Corp Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$26.09 - $40.4 $475,594 - $736,451	-18,229 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$33.06 - $56.93 $602,650 - $1.04 Million	18,229 New	18,229 $697,000
Q4 2020 Feb 16, 2021	SELL	$39.09 - $57.4 $160,269 - $235,340	-4,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$28.43 - $44.67 $116,563 - $183,147	4,100 New	4,100 $178,000
Q2 2019 Aug 14, 2019	SELL	$17.37 - $26.27 $22,789 - $34,466	-1,312 Closed	0 $0

Q1 2019 May 15, 2019	BUY	$10.65 - $25.75 $2,385 - $5,768	224 Added 20.59%	1,312 $31,000
Q4 2018 Feb 14, 2019	SELL	$9.26 - $16.38 $406,569 - $719,180	-43,906 Reduced 97.58%	1,088 $12,000
Q3 2018 Nov 14, 2018	BUY	$7.54 - $18.31 $339,254 - $823,840	44,994 New	44,994 $753,000
Q1 2018 May 15, 2018	SELL	$4.69 - $10.05 $532,511 - $1.14 Million	-113,542 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$7.86 - $9.99 $282,472 - $359,020	-35,938 Reduced 24.04%	113,542 $1.03 Million
Q3 2017 Nov 14, 2017	BUY	$8.89 - $10.4 $1.33 Million - $1.55 Million	149,480	149,480 $1.4 Million

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.